06/19/2014 - 1:33pm

Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.

06/18/2014 - 1:57pm

Canada’s Federal Court ruled recently that the country’s Patented Medicine Prices Review Board — a federal tribunal that regulates pricing on branded medicines — could not extend price-control measures to cover generic drug companies, according to published reports.

06/18/2014 - 12:47pm

A survey co-released Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that 8-in-10 healthcare providers have serious concerns about a proposed Food and Drug Administration rule on generic drug labeling.

06/18/2014 - 10:35am

A survey co-released on Wednesday by the Generic Pharmaceutical Association and the National Coalition on Healthcare reveals that the healthcare providers patients rely on most to explain safety information about their prescription drugs have serious concerns about a proposed FDA rule on generic drug labeling.

06/17/2014 - 11:55am

Lannett Co. received approval from the Food and Drug Administration for codeine sulfate tablets USP, a schedule II controlled substance, in 15 mg, 30 mg and 60 mg dosage strengths.

06/17/2014 - 9:31am

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

06/13/2014 - 9:30am

Following the campaign's six-month anniversary, Fight the Fakes last week announced 11 new partners, bringing the total number of member organizations to 25.

06/13/2014 - 9:06am

Teva Pharmaceutical Industries on Thursday announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb's entecavir compound claim of U.S. Patent No. 5,206,244 invalid.

06/12/2014 - 4:36pm

A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.